Premium
Regulatory Role of N 6 ‐methyladenosine (m 6 A) Methylation in RNA Processing and Human Diseases
Author(s) -
Wei Wenqiang,
Ji Xinying,
Guo Xiangqian,
Ji Shaoping
Publication year - 2017
Publication title -
journal of cellular biochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.028
H-Index - 165
eISSN - 1097-4644
pISSN - 0730-2312
DOI - 10.1002/jcb.25967
Subject(s) - n6 methyladenosine , demethylase , rna , translation (biology) , methyltransferase , rna splicing , rna methylation , biology , epigenetics , messenger rna , microbiology and biotechnology , methylation , untranslated region , genetics , gene
N 6 ‐methyladenosine (m 6 A) modification is an abundant and conservative RNA modification in bacterial and eukaryotic cells. m 6 A modification mainly occurs in the 3′ untranslated regions (UTRs) and near the stop codons of mRNA. Diverse strategies have been developed for identifying m 6 A sites in single nucleotide resolution. Dynamic regulation of m 6 A is found in metabolism, embryogenesis, and developmental processes, indicating a possible epigenetic regulation role along RNA processing and exerting biological functions. It has been known that m 6 A editing involves in nuclear RNA export, mRNA degradation, protein translation, and RNA splicing. Deficiency of m 6 A modification will lead to kinds of diseases, such as obesity, cancer, type 2 diabetes mellitus (T2DM), infertility, and developmental arrest. Some specific inhibitors against methyltransferase and demethylase have been developed to selectively regulate m 6 A modification, which may be advantageous for treatment of m 6 A related diseases. J. Cell. Biochem. 118: 2534–2543, 2017. © 2017 Wiley Periodicals, Inc.